Physician profile
Amy Russo
NPI 1316619901
$1,758.45
in general payments reported to CMS, 2019-2025
39 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $291 · 2023: $556 · 2024: $416 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.14 | 2022-2025 | |
| Janssen Biotech, INC. | $126.83 | 2022-2025 | Erleada |
| Sumitomo Pharma America, INC. | $126.35 | 2023-2024 | Orgovyx, Gemtesa |
| Astrazeneca Pharmaceuticals LP | $86.78 | 2023-2025 | Lynparza, Farxiga, Airsupra |
| Teleflex LLC | $82.23 | 2023 | Urolift |
| Urogen Pharma, INC. | $76.26 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.67 | 2023-2024 | |
| Olympus America INC. | $62.56 | 2023-2024 | Itind System |
| Boston Scientific Corporation | $58.79 | 2022-2025 | Ams 800 Artificial Urinary Sphincter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.72 | 2025 | Jardiance |
| Axonics, INC. | $46.81 | 2023 | Axonics |
| Convatec INC. | $43.14 | 2022 | |
| Astellas Pharma US INC | $41.74 | 2022-2025 | Veozah |
| Foundation Medicine, INC. | $38.45 | 2023 | Foundationone Cdx |
| Ferring Pharmaceuticals INC. | $38.16 | 2024-2025 | Adstiladrin |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.